The safety of the patients who take our medicines is of fundamental importance to AZ.
All medicines have possible side effects that may affect some patients.
We aim to maximise the benefits and minimise the risks of each of our medicines – from discovery through to the end of its useful life.
We have a team of global patient safety specialists dedicated to making sure we deliver on our commitment.
We communicate openly about the safety profile of our medicines to support their appropriate use.
The safety of the patients who take our medicines is of fundamental importance to AstraZeneca.
We work continuously to identify and minimise the risks and maximise the benefits of each of our medicines.
This work starts during the discovery phase of a potential new medicine and continues throughout its development, launch and marketing.
A number of high profile cases in recent years have put the pharmaceutical industry increasingly in the spotlight regarding the safety of medicines.
During the development phase, extensive and rigorous testing is conducted before a medicine can be marketed. Some of the largest clinical trials involve tens of thousands of patients. Despite these large studies, not all side effects can be identified through pre-clinical research and clinical trials. For example, a rare side effect may only occur in one in every 100,000 people, or only become apparent when a medicine has been in use for several years. Therefore, the continued safety monitoring of medicines after their launch is an essential part of our responsibility to patients.
This section describes our commitment to putting patient safety first throughout a medicine’s lifecycle, including how we collect and evaluate safety data and how we communicate safety information to support the safe and effective use of our medicines.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 06:25 GMT
Detailed share price